Geuder Group discussed several new products, including Brilliant Peel vitreoretinal fluid dye and Siluron 2000, during a posterior segment symposium at this year's Euretina meeting.

Following disappointing clinical trial results, Alcon has discontinued its plans to develop anecortave acetate for the prevention of choroidal neovascularization secondary to age-related macular degeneration (AMD).

EyeSite, a free, interactive, self-service vision screening booth developed by Bart Foster of SoloHealth, has been launched, with the first kiosk taking residence in a Wal-Mart store in Georgia, US.

Low doses of Alimera Sciences' Medidur FA provide visual acuity improvements and reduce the risk of ocular side effects commonly associated with corticosteroids, when administered to diabetic macular oedema (DME) patients, according to the three-month interim results of the first human pharmacokinetic (PK) study.

Oertli has launched new instruments to be used in microincision surgery for the anterior and the posterior segments.

The fourth-generation Crystalens HD (Bausch & Lomb) accommodating intraocular lens (IOL) has received FDA marketing approval, five years after the lens was initially launched on the market.

ThromboGenics' experimental enzyme therapy, microplasmin, has been shown to induce a posterior vitreous detachment (PVD) in over 30% of patients in the high dose group, without the need for surgical intervention, according to the results of the Phase IIb MIVI III (Microplasmin for Vitreous Injection) trial.

Durezol (difluprednate ophthalmic emulsion; Sirion Therapeutics) 0.05%, a topical steroid, has received US Food and Drug Administration (FDA) approval for the treatment of postoperative ocular inflammation and pain.

A revolutionary, needle-free technology that has been designed to deliver retina therapies non-invasively, to the back of the eye, has been launched.